Carbon Recycling International (CRI) and Dastur Energy Enter Into a Partnership Agreement for Developing CO2 to Methanol Projects in India
15.9.2022 07:30:00 EEST | Business Wire | Press release
Icelandic environmental technology company Carbon Recycling International (CRI) and Dastur Energy Pvt Ltd, the Indian subsidiary of US based Dastur Energy and a part of the Dastur group of companies, have signed an important partnership agreement for marketing, business development, technology licensing, design and engineering of CO2 to Methanol projects based on CRI’s ETL technology in India.
Carbon Recycling International (CRI) has for the past 15 years established a unique position as a pioneer in the utilization of global carbon dioxide emissions. The company's ETL technology is based on the conversion of carbon dioxide released by industry into methanol, which replaces petroleum raw materials and has a muchlower environmental impact.
Dastur is a leading international consulting engineering firm founded in 1955 focusing on the metals, mining, infrastructure and the energy industry. Its headquarters are in Kolkata, India, with offices around the world. Dastur Energy, specializes in clean energy and energy infrastructure projects and is India's leading organization in the field of carbon capture, and industrial decarbonization.
India's methanol sales are growing rapidly and are now around 2.5 million tonnes annually. The size of the market is expected to reach more than 7.5 million tonnes per year within 10 years. The Indian government supports the increased use of methanol as fuel with the aim of reducing air pollution and greenhouse gas emissions and increasing the share of domestic energy sources in the economy.
"Economically viable methods for utilizing carbon dioxide are key to accelerating global efforts to reduce carbon emissions. We see significant opportunities in India for methanol produced sustainably. CRI's ETL technology solution is one of the most advanced in the world today. We are delighted to collaborate with CRI to bring this unique technology to progressive Indian companies in the public and private sectors, who are seeking green methanol as part of their product offering", said Atanu Mukherjee, CEO of Dastur Energy and Dastur.
CRI has two major projects underway based on its ETL technology. The two plants currently under construction in China will each produce more than 100,000 tons of methanol per year,. directly re-using 150,000 metric tons of carbon dioxide annually as raw material .
"A strong partnership between CRI and Dastur makes it possible to accelerate the introduction and deployment of our sustainable technology solutions to a new market where there are great growth opportunities. Environmentally friendly technologies such as the one developed by CRI will play a key role in the essential transformations in industry and energy markets ahead. It will be a pleasure to see Icelandic environmental technology in the Indian market", said Björk Kristjánsdóttir, CEO of CRI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005880/en/
Contact information
Dastur Energy
http://www.dasturenergy.com/
USA: Abhijit Sarkar
+1 512.823.0398
Abhijit.S@dasturenergy.com
India: Saurav Chatterjee
+91 98313 04985
Saurav.Ch@dastur.com
CRI
https://www.carbonrecycling.is/
Iceland: Omar Sigurbjornsson
+354 865 5736
omar@cri.is
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom